Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2026)

Ginkgo Bioworks Holdings (DNA) has 8 years of Common Equity data on file, last reported at $443.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 31.55% year-over-year to $443.2 million; the trailing twelve-month figure through Mar 2026 stood at $443.2 million (down 31.55% YoY), and the FY2025 full-year result was $508.6 million, down 28.97% from the prior year.
• Common Equity for Q1 2026 stood at $443.2 million, down from $508.6 million in the prior quarter.
• Across five years, Common Equity topped out at $1.7 billion in Q4 2022 and bottomed at $443.2 million in Q1 2026.
• The 5-year median for Common Equity is $987.3 million (2024), against an average of $1.1 billion.
• The widest annual swing landed in 2022, when Common Equity jumped 341.91%; it then tumbled 44.59% in 2024.
• A 5-year view of Common Equity shows it stood at $1.7 billion in 2022, then slumped by 36.81% to $1.1 billion in 2023, then plunged by 34.73% to $716.1 million in 2024, then decreased by 28.97% to $508.6 million in 2025, then dropped by 12.87% to $443.2 million in 2026.
• The last three Common Equity figures came in at $443.2 million (Q1 2026), $508.6 million (Q4 2025), and $559.8 million (Q3 2025), per Business Quant data.

Peer Comparison